Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 6/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13317093 | 0.87 | ADORA1 (0.57) | ADORA1ADORA2BKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL13317080 | 0.79 | ADORA1 (0.66) | ADORA1ADORA2BKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL636328 | 0.77 | ADORA1 (0.62) | ADORA1ADORA2BKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL3548318 | 0.75 | KMT2A (0.47) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL9801808 | 0.74 | KDM4E (0.40) | KDM4EALDH1A1GAAMAPT | |
| SCHEMBL13317101 | 0.72 | ADORA1 (0.46) | ADORA1ADORA2BKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL3521123 | 0.71 | KDM4E (0.44) | KDM4EALDH1A1L3MBTL1GAAMAPT | |
| SCHEMBL19233749 | 0.69 | ADORA1 (0.51) | ADORA1ADORA2BKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL11825494 | 0.69 | ADORA1 (0.55) | ADORA1ADORA2BKDM4EALDH1A1GAA | |
| SCHEMBL9424995 | 0.69 | KDM4E (0.41) | KDM4EALDH1A1L3MBTL1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401838-B1 | NOVEL SUBSTITUTED TETRACYCLIC IMIDAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-26 | — | — | EP | disclosed |
| US-7732437-B2 | Use of anti-histaminics for acute reduction of elevated intracranial pressure | JANSSEN PHARMACEUTICA, NV. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-7732437-B2 | Use of anti-histaminics for acute reduction of elevated intracranial pressure | JANSSEN PHARMACEUTICA, NV. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-7732437-B2 | Use of anti-histaminics for acute reduction of elevated intracranial pressure | JANSSEN PHARMACEUTICA, NV. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-7476662-B2 | Substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-13 | — | — | US | disclosed |
| US-7476662-B2 | Substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-13 | — | — | US | disclosed |
| US-7476662-B2 | Substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-13 | — | — | US | disclosed |
| EP-1451196-B1 | The use of substituted tetracyclic imidazole derivatives as anti-histaminics | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| EP-1451196-B1 | The use of substituted tetracyclic imidazole derivatives as anti-histaminics | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050070525-A1 | Use of anti-histaminics for acute reduction of elevated intracranial pressure | JANSSEN-CILAG GMBH (DE) | 2005-03-31 | — | — | US | disclosed |
| EP-1451196-A1 | THE USE OF ANTI-HISTAMINICS FOR ACUTE REDUCTION OF ELEVATED INTRACRANIAL PRESSURE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-01 | — | — | EP | disclosed |
| US-20040167138-A1 | Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharamaceutical compositions comprising them and their use as a medicine | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-26 | — | — | US | disclosed |
| EP-1401838-A2 | NOVEL SUBSTITUTED TETRACYCLIC IMIDAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003044023-A1 | THE USE OF ANTI-HISTAMINICS FOR ACUTE REDUCTION OF ELEVATED INTRACRANIAL PRESSURE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002100862-A2 | NOVEL SUBSTITUTED TETRACYCLIC IMIDAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070525-A1 | Use of anti-histaminics for acute reduction of elevated intracranial pressure | HRH2, HRH3, HRH4 | ADORA1 96/4885ADORA2B 63/4885KDM4E 3457/4885 |
| US-20040167138-A1 | Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharamaceutical compositions comprising them and their use as a medicine | AIFM1, PTGIS, ATP6V1B2 | ADORA1 1511/4885ADORA2B 1156/4885KDM4E 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.